A Nice recommendation
Nice, the National Institute for Health and Care Excellence, has recommended the use of ribociclib, also known as Kisqali for routine use by the NHS in England and Wales, after it was originally made available through the Cancer Drugs Fund. Their draft guidance recommends ribociclib plus fulvestrant as an option for treating hormone receptor-positive, human…